Aplastic Anemia Research Study
|
Alemtuzumab (Campath) for Refractory or Relapsed Severe Aplastic Anemia
|
Hematologists at the National Heart, Lung, and Blood Institute are investigating a new treatment for Severe Aplastic Anemia (SAA). The study drug, a monoclonal antibody, may help increase blood counts, reduce anemia symptoms, and/or reduce dependence on transfusions. Subjects will receive an intravenous infusion of study medication alemtuzumab (Campath) once a day for 10 days. Subjects will be admitted to the NIH Clinical Center hospital for study drug initiation. If the study drug infusion is tolerated well, the subject may be discharged and receive the remainder of the treatment course as an outpatient.
If you have been diagnosed with SAA and have received prior immunosuppressive therapy and have either failed to respond or have relapsed following treatment, you may be able to participate in this clinical trial. To find out if you qualify, please call our study coordinator at 301-496-4462 or email us at BloodStudy@nhlbi.nih.gov
|
|
 
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Aplastic Anemia Research Study
|
Campath versus r-ATG/CsA versus h-ATG/CsA for previously untreated Severe Aplastic Anemia
|
Researchers at the National Heart, Lung, and Blood Institute of the National Institutes of Health, a part of the Department of Health and Human Services, are investigating methods of treatment for severe aplastic anemia. Hematologists are comparing the effectiveness of three immunosuppressive regimens in previously untreated (no prior immunosuppressive therapy) patients. The study may help increase blood counts, reduce anemia symptoms, and/or reduce dependence on immunosuppressive medications and transfusions. If determined eligible to participate, you (your child) will be selected by a process based on chance to receive one of threee therapies.
If you have been diagnosed with severe aplastic anemia and at least 2 years old, you (your child) may be able to participate in this clinical trial. To find out if you qualify, please call us toll free at 1-800-411-1222 (TTY 1-866-411-1010). Our email address is BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Aplastic Anemia Research Study
|
Daclizumab for Aplastic Anemia
|
If you or someone you know has been diagnosed with aplastic anemia, you may be able to participate in a clinical trial evaluating a new immunosuppressive therapy. Hematologists are evaluating whether daclizumab, a genetically engineered human monoclonal antibody, can increase blood counts, reduce anemia symptoms, and/or reduce dependence on immunosuppressive medications and transfusions.
To find out if you qualify, please contact our research coordinator at (301) 594-4180 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Aplastic Anemia Research Study
|
Eltrombopag in Aplastic Anemia patients with low platelets
|
If you have been diagnosed with aplastic anemia, are18 years old or older, and have a low platelet count, you may be able to participate in a NIH sponsored clinical trial evaluating eltrombopag, a new FDA approved drug that has been shown to help the bone marrow produce more platelets in patients with another disorder that causes a low platelet count, immune thrombocytopenia (ITP). We are studying whether or not this drug can increase the platelet count and/or reduce the need for platelet transfusions in patients with aplastic anemia.
If you qualify for study participation, you will take eltrombopag pills by mouth once a day for three months. While you are taking eltrombopag and for 30 days after you discontinue the drug, we will monitor you closely for side effects. You will need to been seen at least once a month at the NIH, and weekly for blood count monitoring either with your home physician or at the NIH. To find out if you qualify or for more information, please contact our study coordinator 301-402-0797 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Aplastic Anemia Research Study
|
h-ATG for SAA unresponsive to or following a suboptimal response to r-ATG/cyclosporine
|
Hematologists at the National Heart, Lung, and Blood Institute are investigating whether horse anti-thymocyte globulin (h-ATG) may help increase blood counts, reduce anemia symptoms, and/or reduce dependence on transfusions in severe aplastic anemia (SAA) patients who have failed rabbit-ATG. If eligible to participate, consenting subjects will receive an intravenous infusion of study medication h-ATG for 4 days followed by 6 months of oral cyclosporine. Subjects will be admitted to the NIH Clinical Center hospital for study drug initiation. If the study drug infusion is tolerated well, the subject may be discharged and receive the remainder of the treatment course as an outpatient.
If you have been diagnosed with SAA and have received prior immunosuppressive therapy with rabbit-ATG and have either failed to respond or have relapsed following treatment, you may be able to participate in this clinical trial. To find out if you qualify, please call our study coordinator at 301-496-4462 or email us at
BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Aplastic Anemia Research Study
|
Randomized Trial of Campath versus r-ATG/CsA for Severe Aplastic Anemia
|
Researchers at the National Heart, Lung, and Blood Institute of the National Institutes of Health, a part of the Department of Health and Human Services, are investigating a new method of treatment for severe aplastic anemia. Hematologists are comparing the effectiveness of a new immunosuppressive treatment (Campath-1H) with rabbit ATG and Cyclosporine (CsA) therapy for patients with severe aplastic anemia. The study may help increase blood counts, reduce anemia symptoms, and/or reduce dependence on immunosuppressive medications and transfusions.
If you are determined eligible to participate, you will be selected by a process based on chance to receive either (1) Campath-1H for 10 days or (2) rabbit ATG for 5 days + CsA for 6 months.
If you have been diagnosed with severe aplastic anemia and are ages 2 or older , you may be able to participate in this clinical trial. To find out if you qualify, please contact our coordinator at (301) 496-4462 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Aplastic Anemia Research Study
|
Rituximab (Rituxan) for Moderate Aplastic Anemia
|
If you or someone you know has been diagnosed with aplastic anemia you may be able to participate in a clinical trial evaluating a new immunosuppressive therapy. Hematologists are evaluating whether rituximab (Rituxan), a genetically engineered monoclonal antibody therapy, can increase blood counts, reduce anemia symptoms, and/or reduce dependence on immunosuppressive medications and transfusions. If you are determined eligible to participate, you will be treated with an infusion of rituximab once every week for a total of 4 doses and then followed to evaluate for response
To find out if you qualify, please contact our research coordinator at (301) 594-4180 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
| |
|
|
Aplastic Anemia Research Study
|
Stem Cell Transplant for Patients with Aplastic Anemia
|
If you have been diagnosed with aplastic anemia or paroxysmal nocturnal hemoglobinuria (PNH), you may be able to participate in a stem cell transplant clinical trial designed to evaluate methods to decrease graft-versus-host disease, promote engraftment, and improve immune system recovery following a bone marrow stem cell transplant procedure.
You must have an HLA-matched family member to participate. You will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from your donor, which will replace your immune system with the immune system of your healthy donor. Post-transplant therapy is designed to reduce the risk of graft-versus-host disease.
We do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately 3 months. We also provide a daily allowance to help with living expenses while you are on the study and living away from home.
To inquire about eligibility, contact our research coordinator (301) 594-8013 or by e-mail: BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Aplastic Anemia Research Study
|
Umbilical Cord Transplant to Treat Severe Aplastic Anemia
|
If you (or someone you know) has been diagnosed with aplastic anemia, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective for a wide number of diseases and disorders. In this study, we will evaluate the safety and effectiveness using a different type of stem cell transplant procedure, specifically, co-infusion of peripheral blood stem cells from a family member and cord blood stem cells from an unrelated donor.
You must have family member who is willing to participate as a stem cell donor as well as the availability of an HLA matched umbilical cord blood unit (the NIH will conduct the search and procurement) in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 594-8013 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Cancer Research Study
|
Autologous NK cell infusions in treatment resistant Cancer
|
If you (or someone you know) has metastatic cancer of the lung, prostate, colon, rectum, kidney, pancreas or malignant melanoma that is not responding to standard treatments, you may be able to participate in our clinical trial designed to evaluate the safety of a new type of cell therapy. Specifically, we are testing the safety and tolerability of the infusion of a type of your own white blood cells called NK cells.
In this research project, your NK cells will be collected, reproduced to large numbers in the laboratory and then be given back to you as an infusion. Before the cells are given back, you will receive two chemotherapy agents: pentostatin, to suppress your immune system and prevent it from attacking the infused NK cells, and bortezomib, to increase the anti-tumor activity of the NK cells. You will also receive the drug interleukin-2 to maintain NK cell activity. You are required to return to the Clinical Center for frequent safety monitoring over a 7 week period of protocol participation. If you respond you may have the option to continue NK cell infusions.
To find out if you qualify, please call us toll free at 1-800-411-1222 (TTY 1-866-411-1010). Our email address is BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Cancer Research Study
|
Stem Cell Transplant for Treatment of Metastatic Renal Cell (Kidney) Cancer
|
If you have been diagnosed with metastatic renal cell (kidney) cancer, you may be eligible for a stem cell transplant procedure here at the National Institutes of Health (NIH). Under evaluation is whether graft-versus-tumor effects can be generated against renal cell tumors. You must have an HLA-matched family member to participate. You will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from your donor which will replace your immune system with the immune system of your healthy donor. Post-transplant therapy is designed to reduce the risk of graft-versus-host disease.
We do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately 3 months. We also provide a daily allowance to help with living expenses while you are on the study and living away from home.
To inquire about eligibility, contact our research coordinator (301) 594-8013 or by e-mail: BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
| |
|
|
Diamond Blackfan Anemia / Inherited Bone Marrow Failure Syndromes Research Study
|
Daclizumab for Diamond Blackfan Anemia
|
If you or someone you know has been diagnosed with Diamond Blackfan Anemia, you may be able to participate in a clinical trial evaluating a new immunosuppressive therapy. Hematologists are evaluating whether daclizumab, a genetically engineered human monoclonal antibody, can increase blood counts, reduce anemia symptoms, and/or reduce dependence on immunosuppressive medications and transfusions.
To find out if you qualify, please contact our research coordinator at (301) 594-4180 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Diamond Blackfan Anemia / Inherited Bone Marrow Failure Syndromes Research Study
|
Rituximab (Rituxan) for Diamond-Blackfan Anemia
|
If you or your child has been diagnosed with Diamond Blackfan Anemia, you (your child) may be able to participate in a clinical trial evaluating a new immunosuppressive therapy. Hematologists are evaluating whether rituximab (Rituxan), a genetically engineered humanized monoclonal antibody therapy, may increase in the production of red blood cells by the bone marrow and thus a decrease in the number of transfusions needed to prevent symptoms of anemia.
To find out if you qualify, please contact our research coordinator at (301) 594-4180 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Diamond Blackfan Anemia / Inherited Bone Marrow Failure Syndromes Research Study
|
Stem Cell Transplant for Diamond Blackfan Anemia
|
If you (or someone you know) is between the ages of 16-65 years and have been diagnosed with Diamond Blackfan anemia, you may be eligible for a stem cell transplantation procedure at the Clinical Center of the National Institutes of Health (NIH). Under evaluation is the use of low-dose radiation and novel methods of transplant preparation and post transplant therapy to reduce the risk of graft-versus-host disease.
You must have an HLA-matched family member to participate. We will do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately four months. We also provide a small daily allowance to help with living expenses while you are on the study and living away from home.
For more information please contact our research coordinator at (301) 402-3087, or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Autologous NK cell infusions in treatment resistant CLL and CML
|
If you (or someone you know) has CLL or CML that is not responding to standard treatments, you may be able to participate in our phase 1 clinical trial designed to evaluate the safety of a new type of cell transplant. Specifically, we are testing the safety and tolerability of the infusion of one type of your own white blood cells called NK cells.
In this research project your NK cells will be collected, reproduced in large numbers in the laboratory and then given back to you as an infusion. Before the cells are given back, you will receive two chemotherapy agents: pentostatin, to suppress your immune system and prevent it from attacking the infused NK cells, and bortezomib, to increase the anti-tumor activity of the NK cells. You will also receive the drug interleukin-2 to maintain NK cell activity. You are required to return to the Clinical Center for frequent safety monitoring over a 7 week period of protocol participation. If you respond you may have the option to continue NK cell infusions.
To find out if you qualify, please call us toll free at 1-800-411-1222 (TTY 1-866-411-1010). Our email address is BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Escalating Doses of ON 01910.Na for Leukemia
|
Hematologists at the National Heart, Lung, and Blood Institute are investigating a new treatment for chronic lymphocytic leukemia (CLL) and Hairy cell Leukemia. The study drug, ON01910.Na is classified as mitotic inhibitor and works by interrupting the life cycle of leukemia cells. Consenting subjects will receive 2 days of drug infusion once every other week (1 cycle) for a minimum of 2 cycles. Subjects without toxicity will have the option to continue the regimen for 2 additional cycles, after which if there is evidence of response, subjects may continue the regimen indefinitely.
If you are between the ages of 18 and 99 and have been diagnosed with CLL and have failed to respond to, relapsed following, are not eligible for, or opted not to participate in other standard of care treatment options you may be able to participate in a clinical trial. This study will determine what dose and which dosing schedule of this new drug is safe. We will also evaluate whether or not this drug can slow progression of your illness, improve blood counts, and/or reduce the need for transfusions of blood and/or platelets.
To find out if you qualify, please call our study coordinator at 301-402-0797 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Lenalidomide (Revlimid) in CLL and SLL
|
Hematologists at the National Heart, Lung, and Blood Institute are investigating an experimental treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). The study drug--an immune modulator that may block blood vessel growth in cancers--may help normalize blood counts, reduce leukemia-related symptoms, decrease risk of infections and/or improve quality of life and long-term survival. Consenting subjects will take an oral dose of lenalidomide daily for 3 weeks and then no medication for 3 weeks and repeat the regimen 4 times (4 cycles). Response will be measured at 24 weeks. Responding patients will have the option to continue the regimen for 2 additional cycles (if in CR after 4 cycles) or 4 cycles (if in PR after 4 cycles).
If you have been diagnosed with CLL or SLL , have already been treated for CLL or SLL and are 21 years or older, you may be able to participate in this clinical trial. To find out if you qualify, please call our study coordinator at 301-402-0797 or email us atBloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Measurement of residual disease following treatment for CML
|
Researchers at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) are conducting laboratory studies on blood and bone marrow from subjects with chronic myelogenous leukemia (CML) in order to in order to compare the amount of minimally detectable residual disease measured after allogeneic stem cell transplantation or initiation of treatment with a tyrosine kinase inhibitor (Gleevec).
If you or someone you know has been diagnosed and treated for CML you (they) may be able to participate in this sample procurement protocol. Compensation for sample collection procedures is provided.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Natural History of MBL, CLL and SLL
|
The Hematology Branch of the National Heart, Lung, and Blood Institute is conducting a clinical study for previously untreated patients with Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL) or Monoclonal B cell lymphocytosis (MBL). Although all three diseases are considered a type of blood cancer involving B-lymphocytes, CLL involves the peripheral blood, SLL mostly involves the lymph nodes, and MBL is thought to be the earliest diagnostic stage of CLL/SLL.
Most patients with CLL/SLL/MBL do not require treatment at the time of diagnosis and are observed following a "watch and wait" approach. This study provides state of the art diagnostic workup, regular follow-up monitoring, and sample collection during the "watch and wait" period. If treatment becomes necessary, patients will receive information on possible standard treatment options and research studies available at NIH.
If you choose to participate, you will undergo tests and procedures designed to evaluate the status of your disease. You will also have the opportunity to donate blood and tissue samples that will be used in laboratory research experiments designed to help us better understand MBL/CLL/SLL.
If you or someone you know has been diagnosed with MBL, CLL, or SLL you (they) may be able to participate in this study. To find out if you qualify, please contact our research coordinator at (301) 402-0797 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Partially Matched DLI to Treat Relapsed Leukemia
|
If you or someone you know is diagnosed with ALL, AML, or CML and have relapsed within 6 months of receiving a stem cell transplant, you may be able to participate in our clinical trial designed to evaluate the effectiveness of a partially HLA matched infusion of donor lymphocytes (DLI). Specifically, we are testing whether giving an infusion of donor lymphocytes from a partially matched family member will maximize the antileukemia effect of following an HLA matched allogeneic stem cell transplant. To achieve at least temporary engraftment of the DLI and disease control, cyclophosphamide and fludarabine immunosuppression will be given prior to the DLI.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Selectively Depleted Stem Cell Transplant to Treat Leukemia
|
If you or someone you know is diagnosed with ALL, AML, CLL, or CML, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether the special treatment of donor stem cells and immune cells will reduce complications (Graft versus host disease) and improve transplant outcome. You must have an HLA matched brother or sister who is willing to participate as a donor in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Stem Cell Transplant and T Cell Add Back to Treat Leukemia
|
If you or someone you know is diagnosed with acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), or chronic myrlogenous leukemia (CML), you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether special treatment of donor stem cells and delaying the transfusion of donor immune cells will reduce complications and improve transplant outcome. You must have an HLA-matched brother or sister who is willing to participate as a donor in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Stem Cell Transplant for High Risk Patients with Leukemia
|
If you have been diagnosed with ALL, AML, CLL, CML, or CMML you may be able to participate in a stem cell transplant clinical trial designed to evaluate methods to decrease graft-versus-host disease, promote engraftment, and improve immune system recovery following a bone marrow stem cell transplant procedure.
You must have an HLA-matched family member to participate. You will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from your donor, which will replace your immune system with the immune system of your healthy donor. Post-transplant therapy is designed to reduce the risk of graft-versus-host disease.
We do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately 3 months. We also provide a daily allowance to help with living expenses while you are on the study and living away from home.
To inquire about eligibility, contact our research coordinator (301) 594-8013 or by e-mail: BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
WT1 +PR1 peptide vaccination for AML or CML
|
If you are 18 years old or older and have been diagnosed with AML or CML, you may be able to participate in a clinical trial evaluating a new therapy. We believe your immune system might be able to control the abnormal growth of cells that is causing your leukemia. This study will test whether vaccination with a WT1 peptide and a PR1 peptide may increase the number of immune cells responding to your leukemia and thereby slow progression of your illness, improve blood counts, reduce the need for transfusions of blood and platelets, or even achieve a remission for your leukemia Consenting subjects will receive one dose of WT1 vaccine and one dose of PR1 vaccine every other week for 12 weeks (total of 6 vaccinations) followed by post vaccination evaluations 2 weeks and 4 weeks after the last dose of the vaccines.
To find out if you qualify or for more information, please contact or study coordinator at 301-496-3841 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
WT1 peptide vaccination study for Leukemia (AML, ALL, CML or CMML)
|
If you are 18 years old or older and have been diagnosed with AML, ALL, CML or CMML, you may be able to participate in a clinical trial evaluating a new therapy. We believe your immune system might be able to control the abnormal growth of cells that is causing your leukemia. This study will test whether vaccination with a WT-1 peptide may increase the number of immune cells responding to your leukemia and thereby slow progression of your illness, improve blood counts, reduce the need for transfusions of blood and platelets, or even achieve a remission for your leukemia. Consenting subjects will receive two intravenous infusion of fludarabine followed by 9 weekly vaccinations with a WT1 peptide followed by monthly follow up evaluations.
To find out if you qualify or for more information, please contact the study coordinator at 301-496-3841or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Lymphoma Research Study
|
Alemtuzumab (Campath) for T-LGL Lymphoproliferative Disorders
|
Hematologists at the National Heart, Lung, and Blood Institute are investigating a new treatment for T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders. The study drug, a monoclonal antibody, may help increase blood counts and reduce the number of abnormal T cell large granular lymphocytes. If eligible to participate, consenting subjects will receive an intravenous infusion of study medication alemtuzumab (Campath) once a day for 10 days. Subjects will be admitted to the NIH Clinical Center hospital for study drug initiation. If the study drug infusion is tolerated well, the subject may be discharged and receive the remainder of the treatment course as an outpatient.
If you have been diagnosed with T-LGL and are 18 years or older, you may be able to participate in this clinical trial. To find out if you qualify, please call our study coordinator at 301-496-4462 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
| |
|
|
Lymphoma Research Study
|
Escalating Doses of ON 01910.Na for Lymphoma
|
Hematologists at the National Heart, Lung, and Blood Institute are investigating a new treatment for Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma (SLL), Prolymphocytic lymphoma (PLL), or Waldenstrom's Macroglobulinemia (also known as lymphoplasmacytic lymphoma or (WM). The study drug, ON01910.Na is classified as mitotic inhibitor and works by interrupting the life cycle of lymphoma cells. Consenting subjects will receive 2 days of drug infusion once every other week (1 cycle) for a minimum of 2 cycles. Subjects without toxicity will have the option to continue the regimen for 2 additional cycles, after which if there is evidence of response, subjects may continue the regimen indefinitely.
If you are between the ages of 18 and 99 and have been diagnosed with MCL, SLL, PLL or WM and have failed to respond to, relapsed following, are not eligible for, or opted not to participate in other standard of care treatment options you may be able to participate in a clinical trial. This study will determine what dose and which dosing schedule of this new drug is safe. We will also evaluate whether or not this drug can slow progression of your illness, improve adenopathy, improve blood counts and/or reduce the need for transfusions of blood and/or platelets.
To find out if you qualify, please call our study coordinator at 301-402-0797 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Lymphoma Research Study
|
Selectively Depleted Stem Cell Transplant to Treat Lymphoma
|
If you or someone you know is diagnosed with Non- Hodgkin's lymphoma or Mantle cell lymphoma, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether the special treatment of donor stem cells and immune cells will reduce complications (Graft versus host disease) and improve transplant outcome. You must have an HLA matched brother or sister who is willing to participate as a donor in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Lymphoma Research Study
|
Stem Cell Transplant to Treat Lymphoma
|
If you or someone you know is diagnosed with Non- Hodgkin's lymphoma or Mantle Cell lymphoma, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether special treatment of donor stem cells and delaying the transfusion of donor immune cells will reduce complications and improve transplant outcome. You must have an HLA-matched brother or sister who is willing to participate as a donor in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Lymphoma Research Study
|
Stem Cell Transplant and T-Cell Add Back to Treat Lymphoma
|
If you (or someone you know) have been diagnosed with Non- Hodgkin's lymphoma or Mantle cell lymphoma, you may be able to participate in our clinical trial designed to decrease graft-versus- host disease, promote engraftment, and improve immune system recovery following a bone marrow stem cell transplant. Specifically, we are testing whether special treatment of your donor's transplant cells and delaying the transfusion of donor lymphocytes (immune cells) will reduce complications and improve transplant outcome. You must have an HLA-matched brother or sister donor to participate in this trial.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Lymphoma Research Study
|
Stem Cell Transplant for High Risk Patients with Lymphoma
|
If you have been diagnosed with Non-Hodgkin's lymphoma or Hodgkin's Disease you may be able to participate in a stem cell transplant clinical trial designed to evaluate methods to decrease graft-versus-host disease, promote engraftment, and improve immune system recovery following a bone marrow stem cell transplant procedure.
You must have an HLA-matched family member to participate. You will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from your donor, which will replace your immune system with the immune system of your healthy donor. Post-transplant therapy is designed to reduce the risk of graft- versus-host disease.
We do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately 3 months. We also provide a daily allowance to help with living expenses while you are on the study and living away from home.
To inquire about eligibility, contact our research coordinator (301) 594-8013 or by e-mail: BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Multiple Myeloma Research Study
|
Escalating Doses of ON 01910.Na for Multiple Myeloma
|
Hematologists at the National Heart, Lung, and Blood Institute are investigating a new treatment for Multiple Myeloma (MM). The study drug, ON01910.Na is classified as mitotic inhibitor and works by interrupting the life cycle of myeloma cells. Consenting subjects will receive 2 days of drug infusion once every other week (1 cycle) for a minimum of 2 cycles. Subjects without toxicity will have the option to continue the regimen for 2 additional cycles, after which if there is evidence of response, subjects may continue the regimen indefinitely.
If you are between the ages of 18 and 99 and have been diagnosed with MM and have failed to respond to, relapsed following, are not eligible for, or opted not to participate in other standard of care treatment options you may be able to participate in a clinical trial. This study will determine what dose and which dosing schedule of this new drug is safe. We will also evaluate whether or not this drug can slow progression of your illness, improve blood counts, and/or reduce the need for transfusions of blood and/or platelets.
To find out if you qualify, please call our study coordinator at 301-402-0797 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Multiple Myeloma Research Study
|
Selectively Depleted Stem Cell Transplant to Treat Multiple Myeloma
|
If you (or someone you know) have been diagnosed with Multiple Myeloma or Waldenstrom's macroglobulinemia, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether the special treatment of donor stem cells and immune cells will reduce complications (Graft versus host disease) and improve transplant outcome. You must have an HLA matched brother or sister who is willing to participate as a donor in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Multiple Myeloma Research Study
|
Stem Cell Transplant to Treat Multiple Myeloma
|
If you (or someone you know) have been diagnosed with Multiple Myeloma or Waldenstrom's macroglobulinemia, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether special treatment of donor stem cells and delaying the transfusion of donor immune cells will reduce complications and improve transplant outcome. You must have an HLA-matched brother or sister who is willing to participate as a donor in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Mycosis Fungoides / Sezary Syndrome Research Study
|
Stem Cell Transplant for Mycosis Fungoides and Sezary Syndrome
|
If you are between the ages of 18-70 years old and have been diagnosed with Mycosis Fungoides/Sezary Syndrome, you may be eligible for a stem cell transplantation procedure available here at the National Institutes of Health (NIH). Under evaluation in this research study is the use of new methods of transplant preparation and post-transplant therapy to reduce the risk of graft-versus-host disease and to minimize hospital stay.
To participate on the study, you must have an HLA-matched family member who is 18 years old or older. We will do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately four months. We also provide a small daily allowance to help with living expenses while you are on the study and living away from home.
For more information please contact our research recruiter @ 301-594-8013 or BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Myelodysplastic Syndromes (MDS) Research Study
|
Alemtuzumab (Campath-1H) for Myelodysplastic Syndrome (MDS)
|
Hematologists at the National Heart, Lung, and Blood Institute are investigating a new treatment for myelodysplastic syndrome (MDS). The study drug, a monoclonal antibody, may help increase blood counts, reduce anemia symptoms, and/or reduce dependence on transfusions. If eligible to participate, consenting subjects will receive an intravenous infusion of study medication alemtuzumab (Campath-1H) once a day for 10 days. Subjects will be admitted to the NIH Clinical Center hospital for study drug initiation. If the study drug infusion is tolerated well, the subject may be discharged and receive the remainder of the treatment course as an outpatient.
If you have been diagnosed with MDS and are 18 years or older, you may be able to participate in this clinical trial. To find out if you qualify, please call our study coordinator at 301-594-4180 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Myelodysplastic Syndromes (MDS) Research Study
|
Escalating Doses of ON 01910.Na for Myelodysplastic Syndrome (MDS)
|
If you are between the ages of 18 and 85 and have been diagnosed with Myelodysplastic Syndrome (MDS), you may be able to participate in a clinical trial evaluating a new experimental anti-cancer therapy. This study will determine what dose and which dosing schedule of this new drug is safe. We will also evaluate whether or not this drug can slow progression of your illness, improve blood counts, and/or reduce the need for transfusions of blood and/or platelets.
Study participants will receive 3-5 days of drug infusion ( 1 cycle) every other week for a minimum of 2 cycles and a maximum of 8 cycles.
To find out if you qualify or for more information, please contact our study coordinator at 301-594-4180 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Myelodysplastic Syndromes (MDS) Research Study
|
Non-myeloablative stem cell transplant for patients with myelodysplastic syndrome
|
If you have been diagnosed with MDS, you may be able to participate in a stem cell transplant clinical trial designed to evaluate methods to decrease graft versus host disease, promote engraftment, and improve immune system recovery following a bone marrow stem cell transplant procedure.
You must have an HLA-matched family member to participate. You will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from your donor, which will replace your immune system with the immune system of your healthy donor. Post transplant therapy is designed to reduce the risk of graft versus host disease.
We do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately 3 months. We also provide a daily allowance to help with living expenses while you are on the study and living away from home.
To inquire about eligibility, contact our research coordinator at (301) 594-8013 or by e-mail BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Myelodysplastic Syndromes (MDS) Research Study
|
Partially Matched DLI to Treat Relapsed MDS
|
If you or someone you know is diagnosed with myelodysplastic syndrome (MDS) and have relapsed within 6 months of receiving a stem cell transplant, you may be able to participate in our clinical trial designed to evaluate the effectiveness of a partially HLA matched infusion of donor lymphocytes (DLI). Specifically, we are testing whether giving an infusion of donor lymphocytes from a partially matched family member will maximize the antileukemia effect of following an HLA matched allogeneic stem cell transplant. To achieve at least temporary engraftment of the DLI and disease control, cyclophosphamide and fludarabine immunosuppression will be given prior to the DLI.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Myelodysplastic Syndromes (MDS) Research Study
|
Selectively Depleted Stem Cell Transplant to Treat Myelodysplastic Syndrome (MDS)
|
If you (or someone you know) have been diagnosed with Myelodysplastic syndrome, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether the special treatment of donor stem cells and immune cells will reduce complications (Graft versus host disease) and improve transplant outcome. You must have an HLA matched brother or sister who is willing to participate as a donor in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Myelodysplastic Syndromes (MDS) Research Study
|
Stem Cell Transplant to Treat Myelodysplastic Syndrome (MDS)
|
If you (or someone you know) have been diagnosed with Myelodysplastic Syndrome, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether special treatment of donor stem cells and delaying the transfusion of donor immune cells will reduce complications and improve transplant outcome. You must have an HLA-matched brother or sister who is willing to participate as a donor in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Myelodysplastic Syndromes (MDS) Research Study
|
Umbilical Cord Transplant to Treat Myelodysplastic Syndrome (MDS)
|
If you (or someone you know) has been diagnosed with myelodysplastic syndrome, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective for a wide number of diseases and disorders. In this study, we will evaluate the safety and effectiveness using a different type of stem cell transplant procedure, specifically, co-infusion of peripheral blood stem cells from a family member and cord blood stem cells from an unrelated donor.
You must have a family member who is willing to participate as a stem cell donor as well as the availability of an HLA matched umbilical cord blood unit (the NIH will conduct the search and procurement) in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 594-8013 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Myelodysplastic Syndromes (MDS) Research Study
|
WT1 + PR1 peptide vaccine for myelodysplastic syndrome (MDS)
|
If you are 18 years old or older and have been diagnosed with MDS, you may be able to participate in a clinical trial evaluating a new vaccine therapy. We believe your immune system might be able to control the abnormal growth of cells that is causing your MDS. This study will test whether vaccination with a WT1 peptide and a PR1 peptide may increase the number of immune cells responding to your MDS and thereby slow progression of your illness, improve blood counts, reduce the need for transfusions of blood and platelets, or even achieve a remission for your MDS. Consenting subjects will receive one dose of WT1 vaccine and one dose of PR1 vaccine every other week for 12 weeks (total of 6 vaccinations) followed by post vaccination evaluations 2 weeks and 4 weeks after the last dose of the vaccines.
To find out if you qualify or for more information, please contact our study coordinator at 301-496-3841 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Myelodysplastic Syndromes (MDS) Research Study
|
WT1 peptide vaccine study for myelodysplastic syndrome (MDS)
|
If you are 18 years old or older and have been diagnosed with MDS, you may be able to participate in a clinical trial evaluating a new therapy. We believe your immune system might be able to control the abnormal growth of cells that is causing your MDS. This study will test whether vaccination with a WT-1 peptide may increase the number of immune cells responding to your MDS and thereby slow progression of your illness, improve blood counts, reduce the need for transfusions of blood and platelets, or even achieve a remission for your MDS. Consenting subjects will receive two intravenous infusion of fludarabine at the NIH followed by vaccination with a WT1 peptide once a week for 9 weeks followed by monthly follow up evaluations.
To find out if you qualify or for more information, please contact our study coordinator at 301-496-3841 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Paroxysmal Nocturnal Hemoglobinuria (PNH) Research Study
|
Stem Cell Transplant as Treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) have an abnormal blood stem cell population which produces faulty red blood cells which are prematurely destroyed in the circulation. This protocol is designed to determine whether healthy stem cells can replace abnormal PNH stem cells in patients with severe PNH. Blood stem cells which grow to become mature blood cells will be collected from a tissue compatible family member. The patient with PNH will be given chemotherapy followed by a transfusion of stem cells from their donor. The procedure will replace the patients abnormal or "PNH" stem cells with normal healthy stem cells from the donor.
Patients on this study live in the area for approximately four months. We pay for all medical costs related to the transplant. Patients are responsible for living expenses while here, although we provide some daily financial assistance while on study.
To inquire about eligibility, contact our research coordinator at (301) 594-8013 or by e-mail at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
| |
|
|
Pure Red Cell Aplasia Research Study
|
Daclizumab for Pure Red Cell Aplasia
|
If you or someone you know has been diagnosed with Pure Red Cell Aplasia, you may be able to participate in a clinical trial evaluating a new immunosuppressive therapy. Hematologists are evaluating whether daclizumab, a genetically engineered human monoclonal antibody, can increase blood counts, reduce anemia symptoms, and/or reduce dependence on immunosuppressive medications and transfusions.
To find out if you qualify , please contact our research coordinator at (301) 594-4180 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Pure Red Cell Aplasia Research Study
|
Rituximab (Rituxan) for Pure Red Cell Aplasia
|
If you have been diagnosed with Pure Red Cell Aplasia, you may be able to participate in a clinical trial evaluating a new immunosuppressive therapy. Hematologists are evaluating whether rituximab (Rituxan), a genetically engineered monoclonal antibody therapy, can increase blood counts, reduce anemia symptoms, and/or reduce dependence on immunosuppressive medications and transfusions. If you are determined eligible to participate, you will be treated with an infusion of rituximab once every week for a total of 4 doses and then followed to evaluate for response
To find out if you qualify, please contact our research coordinator at (301) 594-4180 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Pure Red Cell Aplasia Research Study
|
Stem Cell Transplant for Patients with Pure Red Cell Aplasia
|
If you have been diagnosed with pure red cell aplasia, you may be able to participate in a stem cell transplant clinical trial designed to evaluate methods to decrease graft-versus-host disease, promote engraftment, and improve immune system recovery following a bone marrow stem cell transplant procedure.
You must have an HLA-matched family member to participate. You will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from your donor, which will replace your immune system with the immune system of your healthy donor. Post-transplant therapy is designed to reduce the risk of graft-versus-host disease.
We do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately 3 months. We also provide a daily allowance to help with living expenses while you are on the study and living away from home.
To inquire about eligibility, contact our research coordinator (301) 594-8013 or by e-mail: BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Sickle Cell Anemia Research Study
|
Collection and Storage of Umbilical Cord Blood for Sickle Cell Disease
|
If you are pregnant and expecting a baby that may have sickle cell disease you might be interested in our research study. We are collecting umbilical cord blood from newborns that may have sickle cell disease and we are freezing the hematopoietic stem cells that are in the cord blood. Hematopoietic stem cells are used in transplant treatment of sickle cell disease; the more cells the doctors use the better the outcome. The goal of our research is to come up with the best ways to harvest, freeze and thaw the stem cells from the umbilical cord blood so when it comes time to use the stem cells for treatment there will be a lot of high quality cells to use.
To be eligible for this program the pregnant mother must be between the ages of 18 - 45 and she must plan to deliver her infant at a hospital in the Washington Metropolitan Area. The pregnant mother needs to attend a meeting with the nurse coordinator in order to go over the program and give consent before labor begins. There is no cost to the family or their insurance carrier for this program.
For further information please contact the research nurse coordinator at
Office phone: 301-594-8381
Fax: 301-594-9153
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
| |
|
|
Sickle Cell Anemia Research Study
|
Inhaled Nitric Oxide and Sildenafil Study
|
Individuals who have sickle cell disease and pulmonary hypertension (increased blood pressure in the lungs) sometimes have more complications (shortness of breath, pain crises, pneumonia, and death). Because of this increased risk, this clinical trial will evaluate if experimental treatments for high blood pressure in the lungs can lower pressures in the lungs and reduce the likelihood of complications. The study has three parts.
The first part involves a thorough screening of your heart and lungs. These tests will be performed on an outpatient or inpatient basis. The second part is specialized testing at the Clinical Center, during which blood pressure in the blood vessels going to your lungs (pulmonary artery) will be measured. The third part of the study is for experimental treament, during which the drug sildenafil will be combined with inhaled nitric oxide gas for 6 weeks. This can be done as either an inpatient or outpatient and you must have been taking sildenafil for 3 months and still have high blood pressure in the lungs.
For more information, please contact study coordinators, Lori Hunter or Wynona Coles at 301-435-2345 or email VascularStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Sickle Cell Anemia Research Study
|
Natural History of Sickle Cell Disease
|
This research protocol allows us to evaluate and treat you because you have sickle cell disease, sickle cell trait, or another anemia or red blood cell disorder such as thalassemia. This will help us gain more understanding of your disease, painful attacks and lung complications often associated with these anemias. You will receive standard medical care for your blood disease and its complications. This means that you will not receive experimental treatment under this protocol.
Your evaluation may also provide information indicating that you are elgible for another protocol at the NIH. If so the other protocol will be discussed with you. You are under no obligation to participate. This study enrolls individuals ages 5 and over.
Please contact our research study nurse at 301-435-2345 or email VascularStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Sickle Cell Anemia Research Study
|
Niacin Therapy in Sickle Cell Disease
|
Niacin is a vitamin that has been shown to improve blood flow in people without sickle cell disease. This study will test whether this is also true in patients with sickle cell disease. In sickle cell disease, abnormal hemoglobin called sickle hemoglobin can interfere with blood flow to cause the symptoms of your disease.
You may be eligible to participate if you are a male or female 18 years of age or older and have sickle cell disease and certain laboratory findings that indicate possible blood flow abnormalities.
For more information please contact Amy Chi at 301-435-2345 or email BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
| |
|
|
Sickle Cell Anemia Research Study
|
Pulmonary Hypertension Research Screening Study
|
Researchers at the NIH invite you to take part in a study that will help us learn how often people with sickle cell anemia develop a complication called pulmonary hypertension. Pulmonary hypertension is a serious disease in which blood pressure in the artery to the lungs is elevated.
You are eligible to participate if you are 18 years of age or older and have sickle cell disease. This study consists of an initial evaluation (including a physical exam, blood tests, and an echocardiogram), a follow-up telephone interview every year after the initial echocardiogram, and a repeat echocardiogram and blood tests approximately two years after the first. There is no cost to participate.
Please contact the study coordinator at 301-402-2104 for more information or email VascularStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Sickle Cell Anemia Research Study
|
Stem Cell Transplant for Sickle Cell Anemia
|
If you (or someone you know) is between the ages of 16-65 years and have been diagnosed with sickle cell anemia, you may be eligible for a stem cell transplantation procedure at the Clinical Center of the National Institutes of Health (NIH). Under evaluation is the use of low-dose radiation and novel methods of transplant preparation and post transplant therapy to reduce the risk of graft-versus-host disease.
You must have an HLA-matched family member to participate. We will do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately four months. We also provide a small daily allowance to help with living expenses while you are on the study and living away from home.
For more information please contact our research coordinator at (301) 402-3087 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Thalassemia Research Study
|
Stem Cell Transplant for Thalassemia
|
Stem Cell Transplantation for Thalassemia
If you (or someone you know) is between the ages of 16-65 years have been diagnosed with thalassemia, you may be eligible for a stem cell transplantation procedure at the Clinical Center of the National Institutes of Health (NIH). Under evaluation is the use of low-dose radiation and novel methods of transplant preparation and post-transplant therapy to reduce the risk of graft-versus-host disease.
You must have an HLA-matched family member to participate. We will do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately four months. We also provide a small daily allowance to help with living expenses while you are on the study and living away from home.
For more information please contact our research coordinator at (301) 402-3087 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
|
|
Department of Health
and Human Services
National
Institutes of Health
National Heart, Lung, and Blood
Institute